Accelerate Diagnostics (AXDX) Q3 2024 earnings summary

Executive summary

• Achieved FDA 510(k) clearance for the Arc system and Blood Culture Kit, and advanced the Wave clinical trial, reinforcing innovation and market leadership.

• Net sales for Q3 2024 were $3.0 million, down 10% year-over-year, with a net loss of $14.6 million for the quarter and $40.5 million for the nine months ended September 30, 2024.

• Gross margin improved to 29% from 3% year-over-year, driven by favorable product mix and absence of prior period inventory write-down.

• Operating expenses decreased significantly, with SG&A at $5.6 million and R&D at $3.8 million for Q3 2024, reflecting cost management.

• Management has substantial doubt about the ability to continue as a going concern due to insufficient resources to fund operations for the next twelve months.

Financial highlights

• Q3 2024 net sales were $3.0 million, a 10% decrease from Q3 2023; consumable product sales rose 9% year-over-year.

• Gross margin was 29% in Q3 2024, up from 3% in Q3 2023; nine-month gross margin was 25%, up from 21% year-over-year.

• Net loss for Q3 2024 was $14.6 million (EPS: -$0.59); year-to-date net loss was $40.5 million (EPS: -$1.78).

• Cash and investments totaled $20.9 million at September 30, 2024, up from $9.7 million at the start of the quarter.

• Cash used in operations was $19.1 million for the nine months ended September 30, 2024.

Outlook and guidance

• Management believes current funding is insufficient to support operations for twelve months and is seeking additional capital or strategic alternatives.

• Plans to submit Wave for FDA review in Q1 2025, with a review timeline of about nine months.

• Expects to convert the majority of existing Pheno customers to Wave upon launch.

• Cash conservation remains a strategic focus, with ongoing efforts to maintain $5 million quarterly cash use.

• If additional funding is not secured, significant operational changes, asset sales, or discontinuation of operations may be required.